ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Osteoprotector Effects of a Milk Product Based on Anthocyans and Enriched in Calcium and Vitamin D

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00663221
Recruitment Status : Completed
First Posted : April 22, 2008
Last Update Posted : July 7, 2009
Sponsor:
Collaborator:
University Hospital, Clermont-Ferrand
Information provided by:
Elvir SAS

Brief Summary:
We hypothesize that anthocyans with calcium and vitamin D have a positive effect on bone reshaping in menopausal women.

Condition or disease Intervention/treatment Phase
Osteoporosis Dietary Supplement: Anthocyans, Calcium and Vitamin D Dietary Supplement: placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Study Start Date : March 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D

Arm Intervention/treatment
Placebo Comparator: 1 Dietary Supplement: placebo
Experimental: 2 Dietary Supplement: Anthocyans, Calcium and Vitamin D




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women
  • Aged between 50 and 65 years
  • Between 1 and 5 years menopause
  • IMC between 19 and 30 kg/m²

Exclusion Criteria:

  • Medical Treatment for bone metabolism
  • Vitamin D not including in the range of 20nmoles<25(OH)<100nmoles/l
  • Vegan and vegetarian diet
  • Regular consumption of food supplementary benefits
  • Lactose intolerance
  • While dieting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00663221


Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63
Sponsors and Collaborators
Elvir SAS
University Hospital, Clermont-Ferrand

ClinicalTrials.gov Identifier: NCT00663221     History of Changes
Other Study ID Numbers: LC2 Atlas
First Posted: April 22, 2008    Key Record Dates
Last Update Posted: July 7, 2009
Last Verified: July 2009

Keywords provided by Elvir SAS:
Osteoporosis prevention

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Vitamins
Vitamin D
Ergocalciferols
Calcium, Dietary
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents